We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In a string of bizarre events that involve violence, lawsuits and a high-profile investment shop, Nasdaq-listed Chinese vaccine maker Sinovac has terminated its plan to take the company private.